Clinical Radiology
Volume 62, Issue 11 , Pages 1021-1035 , November 2007

Imaging in the investigation of paraneoplastic syndromes

  • G.-C. Rutherford

      Affiliations

    • Department of Diagnostic Imaging, Queen's Medical Centre, Nottingham UK
    • Corresponding Author InformationGuarantor and correspondent: G.-C. Rutherford, Department of Diagnostic Imaging, Queen's Medical Centre, Derby Road, Nottingham NG7 2UH, UK. Tel.: +44 0115 9249924 ext 61029; fax: +44 0115 9249243.
    • ,
  • R.A. Dineen

      Affiliations

    • Department of Diagnostic Imaging, Queen's Medical Centre, Nottingham UK
    • ,
  • A. O'Connor

      Affiliations

    • Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK

Received 21 January 2007 ,Revised 4 June 2007 ,Accepted 8 June 2007.

References 

  1. Vedeler CA, Antoine JC, Giometto B, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol. 2006;13:682–690
  2. Recommendations for cross-sectional imaging in cancer management. Ref no. RCR (06)1 London: The Royal College of Radiologists; 2006;
  3. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatr. 2004;75:1135–1140
  4. Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000;123:1481–1494
  5. Urbach H, Soeder BM, Jeub M, et al. Bien CG Serial MRI of limbic encephalitis. Neuroradiology. 2006;48:380–386
  6. Pozo-Rosich P, Clover L, Saiz A, et al. Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol. 2003;54:530–533
  7. Linke R, Schroeder M, Helmberger T, et al. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology. 2004;63:282–286
  8. Younes-Mhenni S, Janier MF, Cinotti L, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain. 2004;127:2331–2338
  9. Shams'ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003;126:1409–1418
  10. Rees JH. Paraneoplastic cerebellar degeneration: new insights into imaging and immunology. J Neurol Neurosurg Psychiatr. 2006;77:427
  11. Bataller L, Graus F, Saiz A, et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus–myoclonus. Brain. 2001;124:437–443
  12. Hayward K, Jeremy RJ, Jenkins S, et al. Long-term neurobehavioural outcomes in children with neuroblastoma and opsoclonus–myoclonus–ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. J Pediatr. 2001;139:552–559
  13. Luque FA, Furneaux HM, Ferziger R, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol. 1991;29:241–251
  14. Araki K, Ueda Y, Hayafuji M, et al. Opsoclonus–myoclonus syndrome with abnormal magnetic resonance imaging and brainstem auditory evoked potentials. Jpn J Med. 1989;28:753–756
  15. Hattori T, Hirayama K, Imai T, et al. Pontine lesion in opsoclonus-myoclonus syndrome shown by MRI. J Neurol Neurosurg Psychiatr. 1988;51:1572–1575
  16. Swart JF, de Kraker J, van der Lely N. Metaiodobenzylguanidine total-body scintigraphy required for revealing occult neuroblastoma in opsoclonus–myoclonus syndrome. Eur J Pediatr. 2002;161:255–258
  17. Antoine J-C, Mosnier J-F, Absi L, et al. Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry. 1999;67:7–14
  18. Molinuevo JL, Graus F, Serrano C, et al. Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol. 1998;44:976–980
  19. Penn AS, Rowland LP. Myasthenia Gravis. In:  Rowland LP editors. Merritt's neurology. 10th ed. Lippincott: Williams and Wilkins; 2000;p. 721–727
  20. Hale DA, Cohen AJ, Schaefer P, et al. Computerized tomography in the evaluation of myasthenia gravis. South Med J. 1990;83:414–416
  21. Skeie GO, Aarli JA, Gilhus NE. Titin and ryanodine receptor antibodies in myasthenia gravis. Acta Neurol Scand. 2006 May;113:19
  22. Ellis K, Austin JH. Jaretzki A 3rd. Radiologic detection of thymoma in patients with myasthenia gravis. AJR Am J Roentgenol. 1988;151:873–881
  23. Batra P, Herrmann C. Mediastinal Imaging in myasthenia gravis: correlation of chest radiography, CT, MR and surgical findings. AJR Am J Roentgenol. 1987;148:515–519
  24. Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330:1797–1810
  25. Fraser RS, Muller NL, Colman N, et al. Diagnosis of diseases of the chest. 4th ed. Philidelphia: WB Saunders; 1999;
  26. Penn AS. Lambert–Eaton syndrome. In:  Rowland LP editors. Merritt's neurology. 10th ed. Lippincott: Williams and Wilkins; 2000;p. 727–728
  27. Nakao YK, Motomura M, Fukudome T, et al. Seronegative Lambert–Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology. 2002;59:1773–1775
  28. O'Neill JH, Murray NMF, Newsom-Davis J. The Lambert–Eaton syndrome. A review of 50 cases. Brain. 1988;111:577–596
  29. Motomura M, Johnston I, Lang B, et al. An improved diagnostic assay for Lambert–Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 1995;58:85–87
  30. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert–Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332:1467–1475
  31. Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert–Eaton myasthenic syndrome. Brain. 1997;120:1279–1300
  32. Wirtz PW, Willcox N, van der Slik AR, et al. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert–Eaton myasthenic syndrome. J Neuroimmunol. 2005;159:230–237
  33. Chalk CH, Murray NM, Newsom-Davis J, et al. Response of the Lambert–Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology. 1990;40:1552–1556
  34. Hettiarachchi RJK, Lok J, Prins MH, et al. Undiagnosed malignancy in patients with deep vein thrombosis: incidence,risk indicators and diagnosis. Cancer. 1998;83:180–185
  35. Nordstrom M, Lindblad B, Anderson H, et al. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ. 1994;308:891–894
  36. Sorenson HT, Mellemkjoer L, Flemming HS, et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998;338:1169–1173
  37. Prandoni P, Lensing AW, Buller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992;327:1128–1133
  38. Prins MH, Hettiarachchi RJ, Lensing AW, et al. Newly diagnosed malignancy in patients with venous thromboembolism. Search or wait and see?. Thromb Haemost. 1997;78:121–125
  39. British Thoracic Society Standards of Care Committee Pulmonary Embolism . British Thoracic Society Guidelines for the management of suspected acute pulmonary embolism. Thorax. 2003;58:470–483
  40. Pinzon R, Drewinko B, Trujillo JM, et al. Pancreatic carcinoma and Trousseau's syndrome: experience at a large cancer. J Clin Oncol. 1986;4:509–514
  41. Evans TR, Mansi JL, Bevan DH. Trousseau's syndrome in association with ovarian carcinoma. Cancer. 1996;77:2544–2549
  42. Tasi SH, Juan CJ, Dai MS, et al. Trousseau's syndrome related to adenocarcinoma of the colon and cholangiocarcinoma. Eur J Neurol. 2004;11:493–496
  43. Sack GH, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine. 1977;56:1–37
  44. Wahrenbrock M, Borsig L, Le D, et al. Selectin–mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest. 2003;112:853–862
  45. Bell WR, Starksen NF, Tong S, et al. Trousseau's syndrome. Devastating coagulopathy in the absence of heparin. Am J Med. 1985;79:423–430
  46. Callander N, Rapaport SI. Trousseau's Syndrome. West J Med. 1993;158:364–371
  47. Batsis JA, Morgenthaler TI. Trousseau syndrome and the unknown cancer: use of positron emission tomographic imaging in a patient with a paraneoplastic syndrome. Mayo Clin Proc. 2005;80:537–540
  48. Sallah S, Sigounas G, Vos P, et al. Autoimmune hemolytic anemia in patients with non-Hodgkin's lymphoma: characteristics and significance. Ann Oncol. 2000;11:1571–1577
  49. Genty I, Michel M, Hermine O, et al. Characteristics of autoimmune hemolytic anemia in adults: retrospective analysis of 83 cases. Rev Med Interne. 2002;23:901–909
  50. Rubinstein I, Langevitz P, Hirsch R, et al. Autoimmune hemolytic anemia as the presenting manifestation of malignant thymoma. Acta Haematol. 1985;74:40–42
  51. Payne D, Muss HB, Homesley HD, et al. Autoimmune hemolytic anemia and ovarian dermoid cysts: case report and review of the literature. Cancer. 1981;48:721–724
  52. Giannadaki E, Potamianos S, Roussomoustakaki M, et al. Autoimmune hemolytic anemia and positive Coombs test associated with ulcerative colitis. Am J Gastroenterol. 1997;92:1872–1874
  53. Plikat K, Rogler G, Scholmerich J. Coombs-positive autoimmune hemolytic anemia in Crohn's disease. Eur J Gastroenterol Hepatol. 2005;17:661–666
  54. Suteanu S, Rohan C, Gherasim E, et al. Hypertrophic osteoarthropathy secondary to bronchopulmonary cancer (our experience). Rom J Intern Med. 1992;30:281–284
  55. Morgan B, Coakley F, Finlay DB, et al. Hypertrophic osteoarthropathy in staging skeletal scintigraphy for lung cancer. Clin Radiol. 1996;51:694–697
  56. Uchisako H, Kazuyoshi S, Tanaka N, et al. Bone scintigraphy in growth hormone-secreting pulmonary cancer and hypertrophic osteoarthropathy. J Nucl Med. 1995;36:822–825
  57. Mito K, Maruyama R, Uenishi Y, et al. Hypertrophic pulmonary osteoarthropathy associated with non small cell lung cancer demonstrated growth hormone-releasing hormone by immunohistochemical analysis. Intern Med. 2001;40:532–535
  58. Olan F, Portela M, Navarro C, et al. Circulating vascular endothelial growth factor concentrations in a case of pulmonary hypertrophic osteoarthropathy. Correlation with disease activity. J Rheumatol. 2004;31:614–616
  59. Davies RA, Darby M, Richards MA. Hypertrophic pulmonary osteoarthropathy in pulmonary metastatic disease. A case report and review of the literature. Clin Radiol. 1991;43:268–271
  60. Biswal BM, Kareem A, Ahmed NM. Hypertrophic osteoarthropathy: an unusual manifestation in nasopharyngeal cancer. Australas Radiol. 2001;45:71–73
  61. Goldstraw P, Walbaum PR. Hypertrophic osteoarthropathy and its occurrence with pulmonary metastases from renal carcinoma. Thorax. 1976;31:205–211
  62. Staalman CR, Umans U. Hypertrophic osteoarthropathy in childhood malignancy. Med Pediatr Oncol. 1993;21:676–679
  63. Rosenthall L, Kirsh J. Observations of radionuclide imaging in hypertrophic pulmonary osteoarthropathy. Radiology. 1976;120:359–362
  64. Kroon HM, Pauwels EK. Bone scintigraphy for the detection and follow-up of hypertrophic osteoartropathy. Diagn Imaging. 1982;51:47–55
  65. Albrecht S, Keller A. Postchemotherapeutic reversibility of hypertrophic osteoarthropathy in a patient with bronchogenic adenocarcinoma. Clin Nucl Med. 2003;28:463–466
  66. Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol. 1995;22:1300–1303
  67. Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer. 2001;85:41–45
  68. Chow WH, Gridley G, Mellemkjaer L, et al. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control. 1995;6:9–13
  69. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357:96–100
  70. Sigurgeirsson B, Lindelof B, Edhag O, et al. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992;326:363–367
  71. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990;323:1729–1735
  72. Mehregan DR, Oursler JR, Leiferman KM, et al. Paraneoplastic pemphigus: a subset of patients with pemphigus and neoplasia. J Cutan Pathol. 1993;20:203–210
  73. Joly P, Richard C, Gilbert D, et al. Sensitivity and specificity of clinical, histologic and immunological features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 2000;43:619–626
  74. Mimouni D, Anhalt GJ, Lazarova Z, et al. Paraneoplastic pemphigus in children and adolescents. Br J Dermatol. 2002;147:725–732
  75. Kaplan I, Hodak E, Ackerman L, et al. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol. 2004;40:553–562
  76. Kahn CR, Flier JS, Bar RS, et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med. 1976;294:739–745
  77. Rigel DS, Jacobs MI. Malignant acanthosis nigricans: a review. J Dermatol Surg Onocl. 1980;6:923–927
  78. Kebria MM, Belinson J, Kim R, et al. Malignant acanthosis nigricans, tripe palms and the sign of Lesr-Tre'lat, a hint to the diagnosis of early stage ovarian cancer: a case report and review of the literature. Gynecol Oncol. 2006;101:353–355
  79. Janier M, Blanchet-Bardon C, Bonvalet D, et al. Malignant acanthosis nigricans associated with non-Hodgkin's lymphoma. Report of 2 cases. Dermatologica. 1988;176:133–137
  80. List AF, Hainsworth JD, Davis BW, et al. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol. 1986;4:1191–1198
  81. Campling BG, Sarda IR, Baer KA, et al. Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer. Cancer. 1995;75:2442–2451
  82. Sorenson JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med. 1995;238:97–110
  83. Tho LM, Ferry DR. Is the paraneoplastic syndrome of inappropriate antidiuretic hormone secretion in lung cancer always attributable to the small cell variety?. Postgrad Med J. 2005;81:17
  84. Gkonos PJ, Hayes T, Burtis W, et al. Squamous carcinoma model of humoral hypercalcaemia of malignancy. Endocrinology. 1984;115:2384–2390
  85. Stewart AF, Romero R, Schwartz PE, et al. Hypercalcaemia associated with gynaecological malignancies: biochemical characterization. Cancer. 1982;49:2389–2394
  86. Grill V, Ho P, Body JJ, et al. Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab. 1991;73:1309–1315
  87. Jacobson JO, Bringhurst FR, Harris NL, et al. Humoral hypercalcaemia in Hodgkin's disease. Clinical and laboratory evaluation. Cancer. 1989;63:917–923
  88. Mundy GR. Pathogenesis of hypercalcaemia of malignancy. Clin Endocrinol. 1985;23:705–714
  89. Onuma E, Azuma Y, Saito H, et al. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcaemia of malignancy refractory to osteoclastic bone resorption inhibitors. Clin Cancer Res. 2005;11:4198–4203
  90. Syed MA, Horwitz MJ, Tedesco MB, et al. Parathyroid hormone-related protein-(1–36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy. J Clin Endocrinol Metab. 2001;86:1525–1531
  91. Yoshimoto K, Yamasaki R, Sakai H, et al. Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcaemia. J Clin Endocrinol Metab. 1989;68:976–981
  92. Nielsen PK, Rasmussen AK, Feldt-Rasmussen U, et al. Ectopic production of intact parathyroid hormone by a squamous cell lung carcinoma in vivo and in vitro. J Clin Endocrinol Metab. 1996;81:3793–3796
  93. Mercier RJ, Thompson JM, Harman GS, et al. Recurrent hypercalcaemia and elevated 1,25-dihydroxy vitamin D levels in Hodgkin's disease. Am J Med. 1988;84:165–168
  94. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348:1656–1663
  95. Clunie GP, Fox PE, Stamp TC. Four cases of acquired hypophosphataemic (“oncogenic”) osteomalacia. Problems of diagnosis, treatment and long-term management. Rheumatology. 2000;39:1415–1421
  96. Garcia CA, Spencer RP. Bone and In-111 octreotide imaging in oncogenic osteomalacia: a case report. Clin Nucl Med. 2002;27:582–583
  97. Roarke MC, Nguyen BD. PET/CT localization of phosphaturic mesenchymal neoplasm causing tumor-induced osteomalacia. Clin Nucl Med. 2007;32:300–301
  98. Gonzalez-Compta X, Manos-Pujol M, Foglia-Fernandez M, et al. Oncogenic osteomalacia: case report and review of head and neck associated tumours. J Laryngol Otol. 1998;112:389–392
  99. Shim SS, Lee KS, Byung-Tae K, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005;236:1011
  100. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol. 1997;4:613–620
  101. Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med. 1997;38(3):343–348
  102. Rees JH, Hain SF, Johnson MR, et al. The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain. 2001;124:2223–2231
  103. Hesse E, Moessinger E, Rosenthal H. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res. 2007;22:158–162
  104. Banayan S, Hot A, Janier M, et al. Malignant mesothelioma of the peritoneum as the cause of a paraneoplastic syndrome: detection by 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2006;33:751
  105. Krug B, Sonet A, Pirson AS, et al. FDG PET utility in paraneoplastic sweet syndrome. Clin Nucl Med. 2004;29:91–92
  106. Berner U, Menzel C, Rinne D, et al. Paraneoplastic syndromes: detection of malignant tumors using (18F) FDG-PET. Q J Nucl Med. 2003;47(2):85–89
  107. Kumar J, Spring M, Carroll PV, et al. 18Fluorodeoxyglucose positron emission tomography in the localization of ectopic ACTH-secreting neuroendocrine tumours. Clin Endocrinol. 2006;64:371–374

PII: S0009-9260(07)00259-0

doi: 10.1016/j.crad.2007.06.005

Clinical Radiology
Volume 62, Issue 11 , Pages 1021-1035 , November 2007

Article Tools

* Image Usage & Resolution